{"id":21231,"date":"2022-02-14T05:10:00","date_gmt":"2022-02-13T21:10:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=21231"},"modified":"2022-02-14T05:44:33","modified_gmt":"2022-02-13T21:44:33","slug":"%e9%a2%84%e5%8d%b0%e8%ae%ba%e6%96%87%ef%bc%9a%e4%ba%ba%e7%b1%bb%e6%8e%a5%e7%a7%8d%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e7%9a%84%e5%ae%89%e5%85%a8%e6%80%a7%e3%80%81%e8%80%90%e5%8f%97%e6%80%a7%e4%b8%8e","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=21231","title":{"rendered":"[\u9884\u5370\u8bba\u6587]\uff1a\u4eba\u7c7b\u63a5\u79cd\u65b0\u51a0\u75c5\u6bd2\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u4e0e\u75c5\u6bd2\u52a8\u529b\u5b66"},"content":{"rendered":"\n<h5 class=\"wp-block-heading\" id=\"article\">ARTICLE<\/h5>\n\n\n\n<h1 class=\"wp-block-heading\" id=\"safety-tolerability-and-viral-kinetics-during-sars-cov-2-human-challenge\">Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge<\/h1>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"ben-killingley-alex-mann-mariya-kalinova-et-alhttps-www-researchsquare-com-article-rs-1121993-v1\">Ben Killingley,\u00a0Alex Mann,\u00a0Mariya Kalinova,\u00a0et al<\/h3>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"ben-killingley-alex-mann-mariya-kalinova-et-alhttps-www-researchsquare-com-article-rs-1121993-v1\">https:\/\/www.researchsquare.com\/article\/rs-1121993\/v1<\/h3>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"ben-killingley-alex-mann-mariya-kalinova-et-alhttps-www-researchsquare-com-article-rs-1121993-v1\">Abstract<\/h2>\n\n\n\n<p>To establish a novel SARS-CoV-2 human challenge model, 36 volunteers aged 18-29 years without evidence of previous infection or vaccination were inoculated with 10 TCID<sub>50<\/sub>\u00a0of a wild-type virus (SARS-CoV-2\/human\/GBR\/484861\/2020) intranasally. Two participants were excluded from per protocol analysis due to seroconversion between screening and inoculation. Eighteen (~53%) became infected, with viral load (VL) rising steeply and peaking at ~5 days post-inoculation. Virus was first detected in the throat but rose to significantly higher levels in the nose, peaking at ~8.87 log<sub>10<\/sub>\u00a0copies\/ml (median, 95% CI [8.41,9.53). Viable virus was recoverable from the nose up to ~10 days post-inoculation, on average. There were no serious adverse events. Mild-to-moderate symptoms were reported by 16 (89%) infected individuals, beginning 2-4 days post-inoculation. Anosmia\/dysosmia developed more gradually in 12 (67%) participants. No quantitative correlation was noted between VL and symptoms, with high VLs even in asymptomatic infection, followed by the development of serum spike-specific and neutralising antibodies. However, lateral flow results were strongly associated with viable virus and modelling showed that twice-weekly rapid tests could diagnose infection before 70-80% of viable virus had been generated. Thus, in this first SARS-CoV-2 human challenge study, no serious safety signals were detected and the detailed characteristics of early infection and their public health implications were shown. ClinicalTrials.gov identifier: NCT04865237.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/assets.researchsquare.com\/files\/rs-1121993\/v1\/427238474bc5657bca55b351.png?maxDims=1200x1200\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/assets.researchsquare.com\/files\/rs-1121993\/v1\/557946b8eb6a2e49f27b3942.png?maxDims=1200x1200\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/assets.researchsquare.com\/files\/rs-1121993\/v1\/f38bdb30a2a149aace05f187.png?maxDims=1200x1200\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/assets.researchsquare.com\/files\/rs-1121993\/v1\/de6c272ac9948508aef6ba26.png?maxDims=1200x1200\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/assets.researchsquare.com\/files\/rs-1121993\/v1\/f8bc9d3957ed48198710abd7.png?maxDims=1200x1200\" alt=\"\"\/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>ARTICLE Safety, tolerability and viral kinetics during  [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21231"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21231"}],"version-history":[{"count":3,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21231\/revisions"}],"predecessor-version":[{"id":21234,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21231\/revisions\/21234"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}